Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR), rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It contains specific transaction data for a single event:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.34 per share.
- Transaction Volume: 46 shares.
- Transaction Date: July 15, 2016.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a routine acquisition of shares by Lady C Witty (PCA of CEO Sir Andrew Witty) resulting from the re-investment of dividends paid on July 14, 2016, within an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of a specific share transaction.
Key Facts for Investor Verification
- Verify the identity of the PCA (Lady C Witty) and her relationship to the CEO (Sir Andrew Witty).
- Confirm the transaction was a dividend re-investment within an ISA, not a market purchase.
- Note that this filing does not reflect the company's overall financial performance for the period.